My uncle’s eGFR is too low. Is surgery the only option?

Question

Hello doctor,

My uncle is 66 and was just diagnosed with muscle-invasive bladder cancer. His biopsy confirmed high-grade urothelial carcinoma. The doctor recommended neoadjuvant chemotherapy followed by radical cystectomy. But, we are concerned about a few things, such as:

Is bladder-sparing treatment an option in some cases, or is surgery always necessary at this stage?
Also, how effective is immunotherapy if he refuses surgery later?
His kidney function (eGFR 52) is borderline; can he tolerate Cisplatin?
Should we be asking about genetic testing or clinical trials at this point?

We are overwhelmed and unsure of how aggressive to be with treatment, given his age and other health issues.

Kindly suggest.

Answer 1

Hello,

Welcome to icliniq.com.

I understand your concern.

Given your uncle’s diagnosis of high-grade muscle-invasive bladder cancer, it is serious but potentially curable with aggressive treatment. The standard approach, as recommended by his doctor, is neoadjuvant chemotherapy followed by radical cystectomy, which offers the best chance for long-term survival.

However, bladder sparing approaches such as trimodal therapy combining transurethral resection, radiation, and concurrent chemotherapy will be considered in select patients, particularly those who are not surgical candidates or strongly wish to avoid cystectomy. These approaches require careful patient selection and close follow-up.

Immunotherapy is generally more effective in metastatic or treatment-refractory settings and is not yet a reliable substitute for surgery in localized muscle-invasive disease. With an eGFR (estimated glomerular filtration rate) of 52, his kidney function is borderline for Cisplatin, which typically requires an eGFR above 60; if he cannot tolerate Cisplatin, alternative regimens may be less effective, and this would need to be weighed carefully.

Genetic or molecular profiling may help guide therapy, especially if bladder-sparing or second-line treatments are being considered. At this stage, it is reasonable to ask about clinical trials, particularly if there are concerns about surgical or chemotherapy tolerance. While his age and health issues add complexity, curative treatment is still a goal, and decisions should balance effectiveness with quality of life.

I hope this helps.

Thank you.